Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Grafalon induction versus basiliximab induction in low-immunologic-risk kidney transplant recipients
MOH_2017-08-08_000707Phase 4Not yet recruiting
- Sponsor
- פרופ' איתן מור
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of antithymocyte globulin rabbit and basiliximab in kidney transplant (2 arms), sponsored by פרופ' איתן מור. Primary endpoints: Acute graft rejection incidence, Patient survival and 1 more. Planned start Feb 2017; status: not yet recruiting.
02
Drugs
antithymocyte globulin rabbitbasiliximab
03
Conditions
kidney transplant
Beyond the preview
Go deeper on MOH_2017-08-08_000707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-08-08_000707.